Should I buy or sell Atreca stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares. View BCEL analyst ratings or view top-rated stocks .

What is Atreca's stock price target for 2024?

4 brokers have issued twelve-month price targets for Atreca's shares. Their BCEL share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 5,094.8% from the stock's current price. View analysts price targets for BCEL or view top-rated stocks among Wall Street analysts .

How have BCEL shares performed in 2024?

Atreca's stock was trading at $0.1320 at the beginning of 2024. Since then, BCEL shares have decreased by 41.7% and is now trading at $0.0770. View the best growth stocks for 2024 here .

Are investors shorting Atreca?

Atreca saw a drop in short interest in March. As of March 15th, there was short interest totaling 148,000 shares, a drop of 45.7% from the February 29th total of 272,700 shares. Based on an average daily trading volume, of 8,350,000 shares, the days-to-cover ratio is presently 0.0 days. View Atreca's Short Interest .

When is Atreca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BCEL earnings forecast .

How were Atreca's earnings last quarter?

Atreca, Inc. (NASDAQ:BCEL) released its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.74) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.74).

What is John Orwin's approval rating as Atreca's CEO?

6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com . John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend.

What other stocks do shareholders of Atreca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC) , Editas Medicine (EDIT) , Kaleido Biosciences (KLDO) , Gossamer Bio (GOSS) , Homology Medicines (FIXX) , Akero Therapeutics (AKRO) , Hookipa Pharma (HOOK) , Lumentum (LITE) , TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL) .

Atreca (BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.

How do I buy shares of Atreca?

Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BCEL

Atreca (BCEL) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free BCEL Stock Alerts

$0.08

+0.00 (+1.18%)

(As of 03:42 PM ET)

Compare

Today's Range: $0.08
▼
$0.09
50-Day Range: $0.06
▼
$0.32
52-Week Range: $0.05
▼
$1.26

Volume: 14,041 shs
Average Volume: 6.91 million shs
Market Capitalization: $3.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Atreca alerts:

Atreca MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 5,094.8% Upside
$4.00 Price Target
Short Interest: Healthy
0.37% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.65) to ($0.65) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.36 out of 5 stars

3.0

Analyst's Opinion

Consensus Rating
Atreca has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Atreca has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.37% of the outstanding shares of Atreca have been sold short.
Short Interest Ratio / Days to Cover
Atreca has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Atreca has recently decreased by 45.73%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Atreca does not currently pay a dividend.
Dividend Growth
Atreca does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Atreca has received a 72.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Atreca is -0.85.

3.0

News and Social Media Coverage

News Sentiment
Atreca has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Atreca this week, compared to 0 articles on an average week.
Search Interest
Only 4 people have searched for BCEL on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Atreca to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atreca insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.30% of the stock of Atreca is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 37.47% of the stock of Atreca is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Atreca are expected to grow in the coming year, from ($1.65) to ($0.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atreca is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atreca is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atreca has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Atreca Stock (NASDAQ:BCEL)

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

BCEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCEL Stock News Headlines

February 18, 2024 | wsj.com

Atreca Inc. Cl A

February 15, 2024 | benzinga.com

Atreca Stock (NASDAQ:BCEL), Short Interest Report

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

February 7, 2024 | msn.com

Atreca Inc Announces Executive Departures and Consulting Agreements

December 29, 2023 | bizjournals.com

Immunome to buy assets from California biotech company

December 26, 2023 | tmcnet.com

BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.

December 21, 2023 | thestreet.com

Atreca Inc.

December 11, 2023 | benzinga.com

Atreca Stock (NASDAQ:BCEL) Dividends: History, Yield and Dates

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

November 16, 2023 | morningstar.com

Atreca Inc Class A BCEL

November 14, 2023 | marketwatch.com

Atreca to Cut About 40% of Workforce

November 14, 2023 | finance.yahoo.com

Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

November 2, 2023 | es.investing.com

Atreca Inc (BCEL)

October 24, 2023 | finance.yahoo.com

BAKER BROS. ADVISORS LP Reduces Stake in Atreca Inc

October 12, 2023 | benzinga.com

What's Going On With Atreca Inc Stock?

October 12, 2023 | bizjournals.com

Mid-Peninsula building rode biotech's boom. Now it's showing how to survive the bust

September 21, 2023 | finance.yahoo.com

Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross

August 11, 2023 | msn.com

HC Wainwright & Co. Downgrades Atreca Inc - (BCEL)

August 11, 2023 | msn.com

Stifel Downgrades Atreca Inc - (BCEL)

August 11, 2023 | finance.yahoo.com

Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring

August 2, 2023 | msn.com

Atreca Inc - (BCEL) Price Target Increased by 11.89% to 10.20

June 20, 2023 | msn.com

Atreca Approaches A Major Go/No-Go Decision

June 6, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Atreca (BCEL)

June 5, 2023 | msn.com

HC Wainwright & Co. Reiterates Atreca Inc - (BCEL) Buy Recommendation

June 5, 2023 | finance.yahoo.com

Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting

June 5, 2023 | markets.businessinsider.com

Atreca (BCEL) Gets a Buy from H.C. Wainwright

June 2, 2023 | fool.com

Atreca (NASDAQ: BCEL)

See More Headlines

Receive BCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atreca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BCEL
CUSIP: N/A
CIK: 1532346
Web: www.atreca.com
Phone: (650) 595-2595
Fax: N/A
Employees: 90
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +5,163.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-97,160,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -157.90%
Return on Assets: -71.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.58
Quick Ratio: 1.58

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.01 per share
Price / Book: 0.04

Miscellaneous

Outstanding Shares: 39,620,000
Free Float: 35,146,000
Market Cap: $3.01 million
Optionable: Optionable
Beta: 1.09

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. John A. Orwin M.B.A. (Age 59)
President, CEO, Director & Principal Financial Officer
Comp: $927.03k
Dr. Tito A. Serafini Ph.D. (Age 61)
Founder & Director
Comp: $665.5k
Mr. Rick Ruiz (Age 60)
Principal Accounting Officer
Ms. Courtney J. Phillips J.D. (Age 49)
General Counsel & Corporate Secretary
Roger Richard Ruiz
Vice President of Finance

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Atreca stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atreca in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCEL, but not buy additional shares or sell existing shares.
View BCEL analyst ratings or view top-rated stocks.
What is Atreca's stock price target for 2024?: 4 brokers have issued twelve-month price targets for Atreca's shares. Their BCEL share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 5,094.8% from the stock's current price.
View analysts price targets for BCEL or view top-rated stocks among Wall Street analysts.
How have BCEL shares performed in 2024?: Atreca's stock was trading at $0.1320 at the beginning of 2024. Since then, BCEL shares have decreased by 41.7% and is now trading at $0.0770.
View the best growth stocks for 2024 here.
Are investors shorting Atreca?: Atreca saw a drop in short interest in March. As of March 15th, there was short interest totaling 148,000 shares, a drop of 45.7% from the February 29th total of 272,700 shares. Based on an average daily trading volume, of 8,350,000 shares, the days-to-cover ratio is presently 0.0 days.
View Atreca's Short Interest.
When is Atreca's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our BCEL earnings forecast.
How were Atreca's earnings last quarter?: Atreca, Inc. (NASDAQ:BCEL) released its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.74) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.74).

What is John Orwin's approval rating as Atreca's CEO?: 6 employees have rated Atreca Chief Executive Officer John Orwin on Glassdoor.com. John Orwin has an approval rating of 100% among the company's employees. This puts John Orwin in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 90.0% of employees surveyed would recommend working at Atreca to a friend.
What other stocks do shareholders of Atreca own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Atreca investors own include Alector (ALEC), Editas Medicine (EDIT), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Homology Medicines (FIXX), Akero Therapeutics (AKRO), Hookipa Pharma (HOOK), Lumentum (LITE), TCR2 Therapeutics (TCRR) and Precision BioSciences (DTIL).
When did Atreca IPO?: Atreca (BCEL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI and Stifel served as the underwriters for the IPO and Canaccord Genuity and Brookline Capital Markets were co-managers.
How do I buy shares of Atreca?: Shares of BCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCEL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Atreca (BCEL) Stock Price, News & Analysis

Atreca MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Atreca Stock (NASDAQ:BCEL)

BCEL Stock Price History

BCEL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BCEL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™